ATB Therapeutics is a biologics company developing therapeutic antibodies with novel cell-killing mechanisms for oncology and immunology therapies.

Axonis Therapeutics is a biotechnology company developing novel neuromedicines targeting neurological disorders like epilepsy and pain.

Aktis Oncology is a clinical-stage biotechnology company developing a proprietary radiopharmaceutical pipeline, including Nectin-4-targeted miniprotein radioconjugates, for cancer treatment.

EyeBio is a clinical-stage ophthalmology biotechnology company focused on developing therapies for sight-threatening eye diseases and has expanded its Series A funding to $130 million.

VectorY Therapeutics is a biotech company focused on developing vectorized antibody therapies for neurodegenerative diseases, with a lead program targeting Amyotrophic Lateral Sclerosis (ALS).